SCIVISION BIOTECH INC. SciVision Biotech Inc. Share Price
Equities
1786
TW0001786002
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108 TWD | -1.37% |
|
+3.85% | +39.18% |
| Sales 2022 | 557M 17.11M 1.37B | Sales 2023 | 713M 21.89M 1.75B | Capitalization | 5.25B 161M 12.9B |
|---|---|---|---|---|---|
| Net income 2022 | 142M 4.36M 349M | Net income 2023 | 178M 5.46M 437M | EV / Sales 2022 | 6.07 x |
| Net cash position 2022 | 206M 6.32M 505M | Net cash position 2023 | 397M 12.19M 975M | EV / Sales 2023 | 6.81 x |
| P/E ratio 2022 |
28.2
x | P/E ratio 2023 |
32.2
x | Employees | - |
| Yield 2022 |
3.69% | Yield 2023 |
3.22% | Free-Float | 65.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.37% | ||
| 1 week | +3.85% | ||
| Current month | +10.88% | ||
| 1 month | +15.76% | ||
| 3 months | +43.81% | ||
| 6 months | +45.95% | ||
| Current year | +39.18% |
1 week
101.50
112.50
1 month
94.20119.00
Current year
73.20119.00
1 year
67.10119.00
3 years
38.80119.00
5 years
33.36119.00
10 years
30.63119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Cheng Han
CEO | Chief Executive Officer | - | 13/06/02 |
Chun Nan Lin
DFI | Director of Finance/CFO | - | - |
Ju Ling Kuo
DFI | Director of Finance/CFO | - | 27/07/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ta Wen Sun
BRD | Director/Board Member | - | - |
Kai Cheng Han
CEO | Chief Executive Officer | - | 13/06/02 |
Shu Lan Yang Li
BRD | Director/Board Member | - | 08/06/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 108 | -1.37% | 380,277 |
| 25/04/24 | 109.5 | +1.39% | 705,992 |
| 24/04/24 | 108 | +0.93% | 570,969 |
| 23/04/24 | 107 | +3.88% | 832,876 |
| 22/04/24 | 103 | -0.96% | 445,563 |
End-of-day quote Taiwan S.E., April 25, 2024
More quotes
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +39.18% | 224M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- 1786 Stock
